Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Adds AAT Deficiency Drug to Pipeline

Premium

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals announced this week that it has formally added ALN-AAT, a subcutaneously delivered therapy for alpha-1 antitrypsin (AAT) deficiency-associated liver disease, to its drug-development pipeline.

AAT deficiency-associated liver disease is caused by accumulation of mutant AAT protein in liver tissue with subsequent liver injury, fibrosis, cirrhosis, and potentially hepatocellular carcinoma, according to the company.

Recently released preclinical data showed that ALN-AAT triggered rapid, potent, dose-dependent, and durable knockdown of mutant AAT protein in the livers of transgenic mouse models, while improving liver histopathology. Treatment also resulted in significant improvements in liver pathology and function, along with reductions in the incidence of liver tumors.

Alnylam said that it anticipates filing an investigational new drug application for ALN-AAT in mid-2015. The drug is one of the company's genetic medicines programs and covered by its recently announced partnership with Genzyme.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.